Small Lymphocytic Lymphoma
📧 Sign up to get email alerts when something new happens for Small Lymphocytic Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2022-12-01Clinical Trial Update: Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 1, Phase 2]
A completed Phase 1/Phase 2 clinical trial evaluating pyrimethamine for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma; re…
-
CLINICAL_TRIALS trial_result · 2022-11-21Clinical Trial Update: Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update on ublituximab for relapsed or refractory B-cell non-Hodgkin lymphoma completed phases 1 and 2.
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy [Phase 3]
A Phase 3 study in previously untreated chronic lymphocytic leukemia (excluding 17p deletion) evaluating debulking regimens before starting …
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies [Phase 2]
Phase 2 clinical trial update on shorter course tacrolimus after non-myeloablative conditioning with related donor PBSCT and high-dose postt…
-
CLINICAL_TRIALS trial_result · 2022-09-28Clinical Trial Update: Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
Phase 2 clinical trial of lenalidomide and obinutuzumab in patients with recurrent or refractory chronic lymphocytic leukemia or small lymph…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-09-19Clinical Trial Update: Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma [Phase 2]
Phase 2 trial evaluating acalabrutinib in combination with the R-ICE chemotherapy regimen for relapsed or refractory lymphoma; the study was…
-
CLINICAL_TRIALS trial_result · 2022-09-10Clinical Trial Update: ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia [Phase 1, Phase 2]
ACP-196 (acalabrutinib), a BTK inhibitor, is being studied in Phase 1/2 trials for chronic lymphocytic leukemia, Richter's syndrome, small l…
-
FDA approval · 2022-09-06FDA Approved: LENALIDOMIDE — Original Application (EXELAN PHARMACEUTICALS INC.)
The FDA approved Exelan Pharmaceuticals Inc.'s original application for lenalidomide, granting approval of a generic version of the cancer d…
-
FDA approval · 2022-08-31FDA Approved: LENALIDOMIDE — Original Application (Alvogen, Inc.)
FDA approved the original application for Lenalidomide from Alvogen, Inc., enabling a generic version of lenalidomide to enter the market.
-
FDA approval · 2022-08-30FDA Approved: LENALIDOMIDE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved lenalidomide as an original application for Mylan Pharmaceuticals Inc., establishing a generic version of lenalidomide.
-
FDA approval · 2022-08-24FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
The FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.
-
CLINICAL_TRIALS trial_result · 2022-07-21Clinical Trial Update: Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma [Phase 2, Phase 3]
Phase 2/3 trial assessing ublituximab + umbralisib with or without bendamustine, and umbralisib alone, in previously treated non-Hodgkin lym…
-
CLINICAL_TRIALS trial_result · 2022-07-20Clinical Trial Update: Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL [Phase 2]
A Phase 2 trial evaluating the combination of lenalidomide and azacitidine for relapsed/refractory chronic lymphocytic leukemia and small ly…
-
FDA approval · 2022-07-06FDA Approved: ZYDELIG — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for ZYDELIG (idelalisib) submitted by Gilead Sciences, Inc. The specific changes to the product'…
-
CLINICAL_TRIALS trial_result · 2022-07-06Clinical Trial Update: A Study to Evaluate ICP-022 in Patients With CLL/ SLL [Phase 1, Phase 2]
Clinical trial update on ICP-022 for chronic lymphocytic leukemia and small lymphocytic lymphoma (early-phase study).
-
FDA label_change · 2022-06-30FDA Approved: LENALIDOMIDE — Supplemental Application (Dr. Reddy's Laboratories Inc.)
FDA approved a supplemental application for lenalidomide submitted by Dr. Reddy's Laboratories Inc., resulting in updated labeling for the d…
-
FDA approval · 2022-06-03FDA Approved: RIABNI — Supplemental Application (Amgen, Inc)
FDA approved a supplemental application for RIABNI (rituximab-arrx) from Amgen. The action updates RIABNI’s labeling to reflect its approved…
-
CLINICAL_TRIALS trial_result · 2022-05-25Clinical Trial Update: Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
Phase 1/2 trial evaluating laboratory-treated T cells in relapsed or refractory B-cell malignancies and acute lymphoblastic leukemia.
-
FDA approval · 2022-05-11FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approved a supplemental application for IMBRUVICA (ibrutinib) from Pharmacyclics LLC.
-
FDA approval · 2022-05-11FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approves a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC. The document indicates FDA approval of the…
-
CLINICAL_TRIALS trial_result · 2022-05-10Clinical Trial Update: Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma [Phase 1]
Phase 1 trial evaluating safety and tolerability of brexucabtagene autoleucel (KTE-X19) in relapsed/refractory chronic lymphocytic leukemia …
-
CLINICAL_TRIALS trial_result · 2022-05-06Clinical Trial Update: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies [Phase 1, Phase 2]
Phase 1/2 trial of acalabrutinib (ACP-196) in combination with pembrolizumab in hematologic malignancies has completed with results posted i…
-
CLINICAL_TRIALS trial_result · 2022-04-19Clinical Trial Update: Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL [Phase 2]
Phase 2 trial update evaluating orelabrutinib with obinutuzumab plus FC in newly diagnosed CLL/SLL.
-
CLINICAL_TRIALS trial_result · 2022-04-11Clinical Trial Update: Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
Phase 2 trial investigating bendamustine and rituximab in combination with copanlisib for chronic lymphocytic leukemia or small lymphocytic …
-
CLINICAL_TRIALS trial_result · 2022-04-05Clinical Trial Update: Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL [Phase 1, Phase 2]
Phase 1/2a dose-escalation study in CLL/SLL and various NHL subtypes completed with results posted.